摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans 3-(2,4-difluorophenyl)-2-propenoic acid chloride | 695186-78-8

中文名称
——
中文别名
——
英文名称
trans 3-(2,4-difluorophenyl)-2-propenoic acid chloride
英文别名
(2E)-3-(2,4-difluorophenyl)prop-2-enoyl chloride;(E)-3-(2,4-difluorophenyl)prop-2-enoyl chloride
trans 3-(2,4-difluorophenyl)-2-propenoic acid chloride化学式
CAS
695186-78-8
化学式
C9H5ClF2O
mdl
——
分子量
202.588
InChiKey
YNLKPSKPONQGFY-DUXPYHPUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    248.8±25.0 °C(Predicted)
  • 密度:
    1.375±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    trans 3-(2,4-difluorophenyl)-2-propenoic acid chloridepotassium carbonate 作用下, 以 甲苯乙腈 为溶剂, 反应 16.75h, 生成 (E)-1-(4-acetylpiperazin-1-yl)-3-[2-fluoro-4-(2-methoxyphenyl)sulfanylphenyl]prop-2-en-1-one
    参考文献:
    名称:
    Discovery of Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 4. Structure−Activity Relationship of Substituents on the Benzene Ring of the Cinnamide
    摘要:
    We have shown that p-arylthio cinnamides can inhibit the interaction of LFA-1 and ICAM-1, which is involved in cell adhesion and the inflammatory process. We now show that 2,3-disubstitution on the aryl portion of the cinnamide results in enhanced activity over mono substitution on the ring. The best 2,3-substituents were chlorine and trifluoromethyl groups. Compounds 39 and 40 which contain two CF3 groups have IC50 values of 0.5 and 0.1 nM, respectively, in inhibiting JY8 cells expressing LFA-1 on their surface, from adhering to ICAM-1. The structure-activity relationship (SAR) was examined using an NMR based model of the LFA-1 I domain/compound 31 complex. One of our compounds (38) was able to reduce cell migration in two different in vivo experiments.
    DOI:
    10.1021/jm0103108
  • 作为产物:
    参考文献:
    名称:
    Pharmaceutically active compounds
    摘要:
    本发明涉及一类通式(I)所示的黑素皮质素MCR4激动剂,其中R1、R2、R3、R4和R5如本文所定义,特别涉及选择性MCR4激动剂化合物,它们在医学上的应用,含有它们的组合物,用于它们制备的工艺以及用于这些工艺的中间体。
    公开号:
    US20050176772A1
点击查看最新优质反应信息

文献信息

  • Benzimidazole cyclooxygenase-2 inhibitors
    申请人:——
    公开号:US20030013886A1
    公开(公告)日:2003-01-16
    This invention provides a compound of the following formula: 1 Or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X 1 and X 2 are independently selected from halo, C 1 -C 4 alkyl, hydroxy, C 1 -C 4 alkoxy, amino, C 1 -C 4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C 1 -C 4 alkyl)thio, (C 1 -C 4 alkyl)sulfinyl, (C 1 -C 4 alkyl)sulfonyl, aminosulfonyl, or the like; R 1 is selected from hydrogen,. straight or branched C 1 -C 4 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 8 cycloalkenyl, phenyl , heteroaryl and the like; R 2 and R 3 are independently selected from hydrogen, halo, C 1 -C 4 alkyl, phenyl and the like; or R 1 and R 2 can form, together with the carbon atom to which they are attached, a C 5 -C 7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.
    本发明提供以下式的化合物:1或其药学上可接受的盐,其中Ar是杂环芳基;X1和X2分别选自卤素,C1-C4烷基,羟基,C1-C4烷氧基,氨基,C1-C4酰基,羧基,氨基甲酰基,氰基,硝基,巯基,(C1-C4烷基)硫基,(C1-C4烷基)亚砜基,(C1-C4烷基)磺酰基,氨基磺酰基,或类似物;R1选自氢,直链或支链C1-C4烷基,C3-C8环烷基,C4-C8环烯基,苯基,杂环芳基等;R2和R3分别选自氢,卤素,C1-C4烷基,苯基等;或R1和R2可以与它们所连接的碳原子一起形成C5-C7环烷基环;m和n分别独立地为0、1、2或3。这些化合物和含有这些化合物的药物组合物在作为镇痛和抗炎药物方面是有用的。
  • Benzimidazole cyclooxygenase-2 inhibitor
    申请人:Pfizer Inc
    公开号:US20040181062A1
    公开(公告)日:2004-09-16
    This invention provides a compound of the following formula: 1 or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X 1 and X 2 are independently selected from halo, C 1 -C 4 alkyl, hydroxy, C 1 -C 4 alkoxy, amino, C 1 -C 4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C 1 -C 4 alkyl)thio, (C 1 -C 4 alkyl)sulfinyl, (C 1 -C 4 alkyl)sulfonyl, aminosulfonyl, or the like; R 1 is selected from hydrogen, straight or branched C 1 -C 4 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 8 cycloalkenyl, phenyl, heteroaryl and the like; R 2 and R 3 are independently selected from hydrogen, halo, C 1 -C 4 alkyl, phenyl and the like; or R 1 and R 2 can form, together with the carbon atom to which they are attached, a C 5 -C 7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.
    这项发明提供了以下公式的化合物:1或其药学上可接受的盐,其中Ar是杂环芳基;X1和X2独立选择自卤素,C1-C4烷基,羟基,C1-C4烷氧基,氨基,C1-C4酰基,羧基,氨基甲酰基,氰基,硝基,巯基,(C1-C4烷基)硫醇基,(C1-C4烷基)亚砜基,(C1-C4烷基)磺酰基,氨基磺酰基等;R1选择自氢,直链或支链C1-C4烷基,C3-C8环烷基,C4-C8环烯基,苯基,杂环芳基等;R2和R3独立选择自氢,卤素,C1-C4烷基,苯基等;或者R1和R2可以与它们所附着的碳原子一起形成C5-C7环烷基环;m和n独立选择自0、1、2或3。这些化合物和含有这些化合物的药物组合物可用作镇痛剂和抗炎剂。
  • Benzimidazole derivatives as cyclooxygenase-2 inhibitors
    申请人:PFIZER INC.
    公开号:EP0937722A1
    公开(公告)日:1999-08-25
    This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof, wherein    Ar is heteroaryl; X1 and X2 are independently selected from halo, C1-C4 alkyl, hydroxy, C1-C4 alkoxy, amino, C1-C4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C1-C4 alkyl)thio, (C1-C4 alkyl)sulfinyl, (C1-C4 alkyl)sulfonyl, aminosulfonyl, or the like; R1 is selected from hydrogen, straight or branched C1-C4 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkenyl, phenyl, heteroaryl and the like; R2 and R3 are independently selected from hydrogen, halo, C1-C4 alkyl, phenyl and the like; or R1 and R2 can form, together with the carbon atom to which they are attached, a C5-C7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.
    本发明提供了一种下式化合物: 或其药学上可接受的盐,其中 Ar 是杂芳基;X1 和 X2 独立选自卤、C1-C4 烷基、羟基、C1-C4 烷氧基、氨基、C1-C4 烷酰基、羧基、氨基甲酰基、氰基、硝基、巯基、(C1-C4 烷基)硫基、(C1-C4 烷基)亚磺酰基、(C1-C4 烷基)磺酰基、氨基磺酰基或类似物;R1 选自氢、直链或支链 C1-C4 烷基、C3-C8 环烷基、C4-C8 环烯基、苯基、杂芳基等;R2 和 R3 独立地选自氢、卤代、C1-C4 烷基、苯基等;或 R1 和 R2 可与所连接的碳原子一起形成 C5-C7 环烷基环;以及 m 和 n 独立地为 0、1、2 或 3。 这些化合物和含有此类化合物的药物组合物可用作镇痛剂和消炎剂。
  • [EN] THIAMINE COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF<br/>[FR] COMPOSÉ THIAMINE, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE ASSOCIÉE<br/>[ZH] 硫胺类化合物、制备方法及其药物组合物
    申请人:SHANGHAI RIXIN BIOTECHNOLOGY CO LTD
    公开号:WO2020108481A1
    公开(公告)日:2020-06-04
    本发明的具体实施方式提供一种硫胺类化合物、制备方法及其药物组合物,所述化合物对Aβ40和/或Aβ42具有抑制作用,特别当与其aa连接的苯乙烯基的苯环未取代、或卤素原子取代时,其化合物对Aβ40和Aβ42均有突出的抑制作用。
  • WO2007/15162
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多